Heading towards an in vivo predictive test for personalized ovarian cancer treatment: application of novel therapies in zebrafish patient derived xenografts Ghent University
Most ovarian cancer patients (+/-900 new cases in Belgium annually) are diagnosed at an advanced stage of the disease, resulting in a poor prognosis. Standard therapy schemes are applied to all epithelial ovarian cancers, but specific histologic subtypes like clear cell carcinoma do not respond and are often excluded from clinical trials. We aim to develop an in vivo predictive test for treatment response. Mice models are currently the gold ...